Use of a dialysis catheter rather than an arteriovenous fi stula is associated with higher dialysis patient mortality. Higher rates of infection account for part of this eff ect. Infl ammation could play an additional role.
Goldstein et al. 1 (this issue) report that a change of dialysis access from a catheter to a fi stula is accompanied by a signifi cant fall in the serum level of C-reactive protein (CRP), and reduction of infl ammation. Th ese fi ndings were in patients who did not have evident catheter infections. Th is should provide yet further impetus to use fi stulas rather than catheters in our hemodialysis patients.
Some issues remain, however. Th e fi rst is that in this report, information on longterm outcome is not provided, either for morbidity and mortality or for quality of life. One can assume that a fall in the CRP level is a good thing, and that such a drop may reduce cardiovascular morbidity and mortality, but assumption is not fact. A second point is that other markers of infl ammation, such as the white blood cell count, were not reported, even though the latter is a long-established correlate of cardiovascular pathology. 2 A fi nal concern is that there can be substantial variation in the CRP level in a given patient, and single values of CRP were used by Goldstein et al. , 1 rather than multiple ones. Still, the patterns of change in CRP levels are distinct and diff er between those who got a fi stula and those who remained with a dialysis catheter.
Catheters are to be avoided, then, not just because they are associated with worse outcomes, but now also because they are a proinfl ammatory stimulus, perhaps contributing by that mechanism to their association with greater mortality. To fi rm up this mechanistic link, one should ask two questions. First, is infl ammation mechanistically important in aff ecting morbidity and mortality in nonrenal disease? Second, are there experimental data to support this link? Th ere is a known surfeit of cardiovascular mortality in subjects with rheumatoid arthritis, an obvious infl ammatory condition. 3 Also, a lipopolysaccharide model of chronic infl ammation in rats caused them to have cardiac fi brosis and microvascular injury. 4 But it is not established that this occurs via CRP. The mechanistic role of CRP can be tested by mendelian randomization. Th is technique identifi es subjects with genetically determined diff erences in a particular trait and tests whether the putative eff ect of that trait indeed corresponds to the genetically determined diff erences. For subjects with metabolic syndrome, genetic variation in CRP did not aff ect cardiovascular outcomes. 5 Th ere are further practical limits. First, there probably is a limit to our ability to reduce mortality in subjects with endstage renal disease. Go et al. show clearly the 15 % yearly mortality of subjects with chronic renal failure who are not (yet) on dialysis. 6 It is hard to imagine that we will be able to reduce the yearly mortality of people on dialysis to a lesser percentage than those 15 % . Second, although it is a laudable goal to reduce catheter use, clinician nephrologists know that this is oft en not possible. Vascular arteriovenous access may be impossible, for instance because of bad vascular disease. So, too, may some patients refuse to have an arteriovenous fi stula created. Th ey prefer the painless access of a catheter, and they do not make the connection between worse outcomes and catheters, in part because those outcomes occur in the hospital and are not visible to them in the outpatient dialysis unit. In future studies comparing catheters with fi stulas, it could be informative to test quality of life, using tools such as the SF-36 health survey.
Nonetheless, it is rational to pay attention to markers of morbidity and future mortality. When the CRP level is above 3 mg / l, a dialysis patient may have an adverse outcome (Figure 1) . Th is may be recognized clinically by a poor appetite, or by the presence of itching. 7, 8 Creating a fi stula should avoid the acknowledged adverse eff ects of a catheter -infection, clotting, underdialysis -and could also reduce the infl ammatory CRP. If that switch in access cannot be made, there may be other measures that may reduce the CRP. The recent JUPITER study reported a benefit of rosuvastatin to reduce the low-density lipoprotein cholesterol and the CRP in subjects without kidney disease, but statins have been tested in dialysis patients and do not improve survival. 9, 10 If lowering of the CRP is still wanted, one can consider treatment for periodontal disease, a Mediterranean diet, and the tasty option of eating dark chocolate. 11 -13 One must also consider whether lowering the blood CRP level is always a good thing, and whether an elevated CRP may have some see original article on page 1063 commentar y good associated with it. Th e CRP molecule has existed for hundreds of millions of years. It is a pentamer exported from the liver and is part of our innate immunity. It assists in bacterial killing, for instance, via complement and via opsonization. It may also assist in eliminating apoptotic and necrotic tissue. 14 Long-term studies of CRP need to watch for any adverse eff ects of hobbling this innate defense.
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